Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab versus sham for VEGF-driven choroidal neovascularization
2012-005417-38Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2013
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ranibizumab in Subretinal neovascularization (2 arms), sponsored by Novartis. Primary endpoint: Best corrected visual acuity change from baseline to Month 2. Started May 2013; status: completed.
02
Drugs
ranibizumab
03
Conditions
Subretinal neovascularization
Beyond the preview
Go deeper on 2012-005417-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005417-38.